China’s healthcare & life sciences industry is currently experiencing significant growth with foreign multinational corporations (MNCs) continuously investing in the Chinese market. The implementation of healthcare reforms by the Chinese government and other regulatory bodies have and will continue to significantly impact business practices and operational costs of companies in this industry.
In our first issue, we highlight common tax and customs matters with an emphasis on R&D activities relating to daily business operations within China’s healthcare & life sciences industry. We also explore potential tax planning ideas to optimise business models for companies in this particular industry with an objective to improve tax efficiency and expedite goods importation.
© 2021 KPMG Huazhen LLP, a People's Republic of China partnership, KPMG Advisory (China) Limited, a limited liability company in China, KPMG, a Macau partnership and KPMG, a Hong Kong partnership, are member firms of the KPMG global organisation of independent member firms affiliated with KPMG International Limited ("KPMG International"), a private English company limited by guarantee. All rights reserved. The KPMG name and logo are registered trademarks or trademarks of KPMG International.
For more detail about the structure of the KPMG global organisation please visit https://home.kpmg/governance.